The global fill-finish pharmaceutical contract manufacturing market was valued at USD 18.0 billion in 2024 and is expected to reach USD 29.1 billion by 2030, expanding at a CAGR of 8.3% from 2025 to 2030. The market is projected to grow from USD 21.1 billion in 2026 to USD 29.1 billion by 2030.

North America held the leading position in 2024, accounting for 34.9% of global revenue. The growing tendency of pharmaceutical and biopharmaceutical companies to outsource fill-finish activities is one of the major factors supporting market expansion.

Key Market Trends & Insights

Outsourcing becomes a strategic manufacturing model

Pharmaceutical companies are increasingly transferring fill-finish activities to specialized contract manufacturing organizations (CMOs). This approach allows drug developers to concentrate resources on core activities such as drug discovery and development while reducing operational complexity, manufacturing risks, and capital requirements.

Injectable drug demand strengthens service requirements

The expanding use of injectable medicines is creating greater demand for reliable fill-finish manufacturing capabilities. Increasing rates of chronic conditions, including diabetes and cardiovascular diseases, are contributing to the need for injectable therapies and, consequently, specialized manufacturing capacity.

Biologics require specialized fill-finish capabilities

The continued expansion of biologics, including monoclonal antibodies and vaccines, is increasing demand for sophisticated fill-finish services. Contract manufacturers with capabilities for complex biologics, high-potency products, and large-volume production are positioned to benefit from this shift.

Technology is improving manufacturing efficiency

Advances in fill-finish technologies are helping manufacturers improve production efficiency, quality, and regulatory compliance. These developments are particularly important as manufacturers handle increasingly complex biological products while meeting stringent quality requirements.

Emerging markets are attracting manufacturing investment

Healthcare investment and pharmaceutical manufacturing initiatives across emerging markets are creating additional opportunities for contract manufacturers. Saudi Arabia and India are among the markets where investment in healthcare infrastructure and domestic pharmaceutical capabilities is supporting the development of local manufacturing ecosystems.

Download a free sample report or claim your copy of this full market intelligence report

Segment Highlights

• Molecules: Large molecules led the market with a 67.3% revenue share in 2024.
• End-use: Biopharmaceutical companies accounted for the largest share at 55.3% in 2024.
• Product: Vials represented the dominant product category, with a 53.4% share in 2024.
• North America: The region accounted for 34.9% of global revenue in 2024.
• U.S.: The U.S. represented 88.3% of North America's revenue in 2024.
• Regional outlook: North America was the largest market in 2024, while Asia Pacific is expected to be the fastest-growing regional market.

Market Size & Forecast

What Is Driving Demand for Fill-finish Services?

The increasing prevalence of chronic diseases is supporting demand for injectable medicines, while the growth of biologics is creating requirements for specialized manufacturing and handling capabilities. Together, these trends are encouraging pharmaceutical companies to rely more heavily on experienced CMOs.

Outsourcing also offers manufacturers a way to reduce investment requirements and operational risks. By transferring specialized production activities to external partners, pharmaceutical companies can focus more heavily on research, development, commercialization, and other core competencies.

Healthcare expenditure growth in Asia Pacific is another factor creating opportunities for fill-finish providers. The supplied market analysis highlights increased healthcare spending in India and China and points to the need for dependable pharmaceutical manufacturing infrastructure following the COVID-19 period.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs.

Regulatory and Technology Developments

Regulatory improvements and manufacturing innovation are influencing the competitive environment. Regulatory authorities such as China's NMPA and Argentina's ANMAT are contributing to faster approval processes, supporting pharmaceutical development and manufacturing activity.

Technological improvements are also enabling manufacturers to address more complex products while maintaining quality and regulatory compliance. In June 2024, Lonza introduced the Capsugel Enprotect size 9 capsule for pre-clinical testing of acid-sensitive APIs in rodents, with the stated objective of streamlining testing and supporting faster drug development timelines.

Regional Expansion and Strategic Partnerships

Emerging pharmaceutical markets are increasingly emphasizing local manufacturing capabilities. Partnerships between domestic pharmaceutical companies and international CMOs can help address growing demand while strengthening regional production infrastructure.

Saudi Arabia provides an example of this trend. In June 2023, the country's Public Investment Fund launched Lifera, a CDMO focused on local biopharmaceutical manufacturing. The initiative aims to expand domestic manufacturing capacity and strengthen the supply of essential medicines in alignment with Vision 2030.

Such investments and strategic collaborations can support the development of regional pharmaceutical manufacturing ecosystems and create opportunities for specialized fill-finish service providers.

Explore the full list of profiled companies operating in this market with recent strategic initiatives

Leading Fill-finish Pharmaceutical Contract Manufacturing Companies

Key companies identified in the supplied market analysis include:

• Thermo Fisher Scientific Inc.
• Sartorius AG
• Boehringer Ingelheim International GmbH
• Catalent, Inc. (acquired by Novo Holdings A/S)
• Societal CDMO (Recro Pharma, Inc.)
• Baxter
• Eurofins Scientific
• Symbiosis Pharmaceutical Services Ltd.
• MabPlex International Co. Ltd.

Explore our dedicated business services:

Prism AI: Market Intelligence with Cited Research- Ask questions in plain language and get insights drawn from Grand View Research's entire research library, with sources cited. Create your free account today.

U.S. Healthcare Facility Mapping & Intelligence Platform: Get facility-level intelligence to guide smarter decisions. Sign up Today